ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Inozyme Pharma Inc

Inozyme Pharma Inc (INZY)

5.33
0.01
(0.19%)
Closed July 20 4:00PM
5.33
-0.01
(-0.19%)
After Hours: 7:13PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
5.33
Bid
4.97
Ask
5.67
Volume
118,868
5.28 Day's Range 5.48
2.689 52 Week Range 7.795
Market Cap
Previous Close
5.32
Open
5.39
Last Trade
50
@
5.25
Last Trade Time
Financial Volume
$ 636,834
VWAP
5.3575
Average Volume (3m)
360,733
Shares Outstanding
61,855,509
Dividend Yield
-
PE Ratio
-4.64
Earnings Per Share (EPS)
-1.15
Revenue
-
Net Profit
-71.17M

About Inozyme Pharma Inc

Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 ... Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Inozyme Pharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker INZY. The last closing price for Inozyme Pharma was $5.32. Over the last year, Inozyme Pharma shares have traded in a share price range of $ 2.689 to $ 7.795.

Inozyme Pharma currently has 61,855,509 shares outstanding. The market capitalization of Inozyme Pharma is $329.07 million. Inozyme Pharma has a price to earnings ratio (PE ratio) of -4.64.

INZY Latest News

Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency

BOSTON, July 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics...

Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)

BOSTON, June 21, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics...

Inozyme Pharma to Present at the Jefferies Global Healthcare Conference

BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics...

Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences

BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics...

Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference

BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics...

Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights

- Interim data from SEAPORT-1, a Phase 1 trial of INZ-701 in patients with end-stage kidney disease receiving hemodialysis, on track for fourth quarter of 2024 - - Interim data from ENERGY-1, a...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.234.509803921575.15.8255.0153577915.47980084CS
40.9521.68949771694.385.8254.323728984.75727337CS
12123.09468822174.335.8254.233607334.66890118CS
261.126.00472813244.237.7954.1155200925.45600929CS
52-0.69-11.46179401996.027.7952.6895318044.90462243CS
156-12.42-69.971830985917.7519.580.9914273934.50468062CS
260-12.6-70.273284997217.9331.64990.9913370965.33475901CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SERVServe Robotics Inc
$ 7.51
(185.55%)
266.26M
AUGXAugmedix Inc
$ 2.27
(147.71%)
24.14M
XCURExicure Inc
$ 0.5351
(76.02%)
14.02M
PSNLPersonalis Inc
$ 3.83
(56.33%)
22.8M
MDBHMDB Capital Holdings LLC
$ 10.675
(37.21%)
126.45k
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
124.61M
HYZNHyzon Motors Inc
$ 0.149
(-47.54%)
23.63M
MEDSTRxADE Health Inc
$ 14.92
(-33.45%)
223.27k
SILOSilo Pharma Inc
$ 2.50
(-27.95%)
11.93M
KITTNauticus Robotics Inc
$ 0.0935
(-27.46%)
28.43M
SERVServe Robotics Inc
$ 7.51
(185.55%)
266.26M
SXTP60 Degrees Pharmaceuticals Inc
$ 0.2602
(5.77%)
226.82M
NVDANVIDIA Corporation
$ 117.93
(-2.61%)
217.11M
SQQQProShares UltraPro Short QQQ
$ 8.46
(2.79%)
188.2M
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
124.61M

INZY Discussion

View Posts
AJ Freely AJ Freely 12 months ago
$INZY - 👆Up 7% Pre-Market/ Current Price $5.12
Pivotal bioVenture Partners Fund I, L.P purchases
835k shares equal to $4m investment
👍️0
Monksdream Monksdream 12 months ago
INZY new 52 week high
👍️0
INFINITI INFINITI 1 year ago
Loading
👍️0
Jess070283 Jess070283 1 year ago
Have a feeling this about to squeeze into a halt soon…..
👍️0
tj9938 tj9938 2 years ago
Great week so far. Gotta keep it movin.
👍️0
tj9938 tj9938 2 years ago
Quietest board out there
👍️0
ErnieBilco ErnieBilco 2 years ago
Grabbed a starter here today
👍️0
crudeoil24 crudeoil24 2 years ago
INZ-701 is currently in a Phase 1/2 clinical trial for ENPP1 Deficiency. Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com
👍️0
crudeoil24 crudeoil24 2 years ago
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. It is also focused on developing a therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-binding cassette sub-family C member 6 (ABCC6) deficiencies. The Company's lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
👍️0
crudeoil24 crudeoil24 2 years ago
Inozyme Pharma 13G Filing From Deep Track Capital Shows New 8.11% Stake

(i) Deep Track Capital, LP

(ii) Deep Track Biotechnology Master Fund, Ltd.

(iii) David Kroin

INZY
👍️0
tw0122 tw0122 2 years ago
I like the BioXc chart looks better. Thanks for all the good insight.
👍️0
crudeoil24 crudeoil24 2 years ago
The offering is expected to close on or about April 19, 2022
👍️0
tw0122 tw0122 2 years ago
This analyst know about the offering?
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the pricing of an underwritten offering of 16,276,987 shares of its common stock at a price of $3.69 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 3,523,013 shares of common stock at a price of $3.6899 per pre-funded warrant, for aggregate gross proceeds of approximately $73 million, before deducting underwriting discounts and commissions and other offering expenses. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of such pre-funded warrant. All of the securities are being offered by Inozyme. The offering is expected to close on or about April 19, 2022, subject to customary closing conditions.
👍️0
crudeoil24 crudeoil24 2 years ago
PT > 33.00
👍️0
crudeoil24 crudeoil24 2 years ago
H.C. Wainwright analyst Edward White maintained a Buy rating on Inozyme Pharma (INZY – Research Report) yesterday and set a price target of $33.00. The company's shares closed last Tuesday at $3.89, close to its 52-week low of $3.54. According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of -19.5% and a 25.5% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics. Inozyme Pharma has an analyst consensus of Strong Buy, with a price target consensus of $30.00, a 541.0% upside from current levels.
👍️0

Your Recent History

Delayed Upgrade Clock